Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Dec;74(11):1709–1713. doi: 10.1038/bjc.1996.619

Combined effect of clinically relevant doses of emitefur, a new 5-fluorouracil derivative, and radiation in murine tumours.

Y Shibamoto 1, R Murata 1, S Miyauchi 1, M Hirohashi 1, T Takagi 1, K Sasai 1, T Shibata 1, N Oya 1, M Takahashi 1
PMCID: PMC2077217  PMID: 8956782

Abstract

We investigated the combined effect of radiation and clinically relevant doses of emitefur (BOF-A2), a newly developed anti-cancer agent consisting of a masked form of 5-fluorouracil (5-FU) and a potent inhibitor of 5-FU degradation, in two types of murine tumours. In preliminary pharmacokinetic studies, the area under the curve for 5-FU in plasma, after administration of 12.5 mg kg-1 and 25 mg kg-1 emitefur in mice, appeared to be similar to that obtained on the first day and that on the seventh day, respectively, after starting administration of 400-600 mg day-1 in humans. These doses (12.5 and 25 mg kg-1) of emitefur were evaluated either alone or in combination with single (15 Gy), five-fraction (4 Gy each) or ten-fraction (2.8 Gy each) irradiation using a tumour growth delay assay for SCCVII tumours and in combination with four-fraction (5 Gy each) irradiation using an in vivo-in vitro assay for EMT6 tumours. The anti-tumour and radiation-enhancing effects of 12.5 mg kg-1 emitefur were not significant in any except the ten-fraction experiment. On the other hand, multiple doses of 25 mg kg-1 emitefur given either alone or in combination with radiation produced marked effects. The mean tumour growth delay time (the time to double in volume for treated tumours minus that for untreated tumours) was 8.1 days for five administrations of 25 mg kg-1 emitefur. 10.4 days for five fractions of 4 Gy and 22.1 days for five treatments with the combination of the two. Thus, the increase in growth delay afforded by this combination was at least additive. The effect of four fractions of 5 Gy with 25 mg kg-1 emitefur in EMT6 tumours was lower than that of four fractions of 7.5 Gy, but the effect of five fractions of 4 Gy with this dose of emitefur in SCCVII tumours was similar to the effect of five fractions of 6 Gy, and the effect of ten fractions of 2.8 Gy with 25 mg kg-1 emitefur was much higher than that of ten fractions of 4.2 Gy. In conclusion, emitefur given either alone or in combination with radiation appears to have a significant anti-tumour effect even at clinically relevant dose levels, although a threshold dose exists between 12.5 and 25 mg kg-1. Further clinical studies of this compound are warranted.

Full text

PDF
1709

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buchholz D. J., Lepek K. J., Rich T. A., Murray D. 5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells. Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1053–1058. doi: 10.1016/0360-3016(94)00654-4. [DOI] [PubMed] [Google Scholar]
  2. Fraile R. J., Baker L. H., Buroker T. R., Horwitz J., Vaitkevicius V. K. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res. 1980 Jul;40(7):2223–2228. [PubMed] [Google Scholar]
  3. Fujii S., Fukushima M., Shimamoto Y., Ohshimo H., Imaoka T., Shirasaka T. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn J Cancer Res. 1989 Feb;80(2):173–181. doi: 10.1111/j.1349-7006.1989.tb02286.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Harada M., Nishitani H., Koga K., Miura I., Kimura A. Comparative studies on the metabolism of new fluorinated pyrimidine drugs in the liver by in vivo 19F magnetic resonance spectroscopic observation. Jpn J Cancer Res. 1993 Feb;84(2):197–202. doi: 10.1111/j.1349-7006.1993.tb02855.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hillcoat B. L., McCulloch P. B., Figueredo A. T., Ehsan M. H., Rosenfeld J. M. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer. 1978 Dec;38(6):719–724. doi: 10.1038/bjc.1978.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lawrence TS, Maybaum J. Fluoropyrimidines as Radiation Sensitizers. Semin Radiat Oncol. 1993 Jan;3(1):20–28. doi: 10.1053/SRAO00300020. [DOI] [PubMed] [Google Scholar]
  7. Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
  8. Miyauchi S., Imaoka T., Okada T., Motoyama M., Kawaguchi T., Akiyama H., Odomi M. Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats. Jpn J Pharmacol. 1996 Feb;70(2):139–148. doi: 10.1254/jjp.70.139. [DOI] [PubMed] [Google Scholar]
  9. Miyauchi S., Imaoka T., Utsunomiya T., Hayashi K., Kubo M., Kawaguchi T., Matsui Y. Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels. Jpn J Cancer Res. 1994 Jun;85(6):665–668. doi: 10.1111/j.1349-7006.1994.tb02411.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Moertel C. G., Frytak S., Hahn R. G., O'Connell M. J., Reitemeier R. J., Rubin J., Schutt A. J., Weiland L. H., Childs D. S., Holbrook M. A. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981 Oct 15;48(8):1705–1710. doi: 10.1002/1097-0142(19811015)48:8<1705::aid-cncr2820480803>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  11. Murata R., Shibamoto Y., Miyauchi S., Hirohashi M., Takagi T., Sasai K., Oya N., Hiraoka M. The combined antitumour effect of a new 5-fluorouracil derivative, BOF-A2, and radiation in vivo. Br J Cancer Suppl. 1996 Jul;27:S114–S116. [PMC free article] [PubMed] [Google Scholar]
  12. Nakai Y., Furuse K., Ohta M., Yamaguchi Y., Fujii M., Asakawa M., Fukuoka M., Yoshida K., Niitani H. Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study. Acta Oncol. 1994;33(5):523–526. doi: 10.3109/02841869409083929. [DOI] [PubMed] [Google Scholar]
  13. Okayasu T., Sugiyama K., Miyauchi S. Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues. Jpn J Cancer Res. 1994 Jan;85(1):101–105. doi: 10.1111/j.1349-7006.1994.tb02892.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sanchíz F., Millá A., Torner J., Bonet F., Artola N., Carreño L., Moya L. M., Riera D., Ripol S., Cirera L. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1347–1350. doi: 10.1016/0360-3016(90)90342-h. [DOI] [PubMed] [Google Scholar]
  15. Seifert P., Baker L. H., Reed M. L., Vaitkevicius V. K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975 Jul;36(1):123–128. doi: 10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  16. Shibamoto Y., Komuro C., Takahashi M., Ono K., Abe M. The effect of N6-butyrylcordycepin on potentially lethal damage repair in vivo. J Radiat Res. 1985 Dec;26(4):404–410. doi: 10.1269/jrr.26.404. [DOI] [PubMed] [Google Scholar]
  17. Shibamoto Y., Sasai K., Abe M. The radiation response of SCCVII tumor cells in C3H/He mice varies with the irradiation conditions. Radiat Res. 1987 Feb;109(2):352–354. [PubMed] [Google Scholar]
  18. Shibamoto Y., Yukawa Y., Tsutsui K., Takahashi M., Abe M. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res. 1986 Sep;77(9):908–915. [PubMed] [Google Scholar]
  19. Shirasaka T., Fujita F., Fujita M., Fukushima M., Taguchi T., Fujii S. [Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice]. Gan To Kagaku Ryoho. 1990 Sep;17(9):1871–1876. [PubMed] [Google Scholar]
  20. Tatsumi K., Yamauchi T., Kiyono K., Kishi K., Yanagihara Y., Imaoka T., Kawaguchi T., Kubo M. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. J Biochem. 1993 Dec;114(6):912–918. doi: 10.1093/oxfordjournals.jbchem.a124276. [DOI] [PubMed] [Google Scholar]
  21. Weinberg M. J., Rauth A. M. 5-Fluorouracil infusions and fractionated doses of radiation: studies with a murine squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 1987 Nov;13(11):1691–1699. doi: 10.1016/0360-3016(87)90166-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES